Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Belite Bio, Inc. (BLTE) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference and conduct a virtual presentation on February 14, 2024. The company focuses on developing therapeutics for degenerative retinal diseases with unmet medical needs. The webcast of the presentation can be accessed on the investor relations section of the Belite Bio website. The replay will be available for 90 days.

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34^th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When will Belite Bio participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

Belite Bio will participate in the conference on February 13-14, 2024.

What is the focus of Belite Bio's drug development?

Belite Bio focuses on advancing novel therapeutics targeting degenerative retinal diseases with unmet medical needs.

Where can the webcast of Belite Bio's virtual presentation be accessed?

The webcast can be accessed under the 'Events' tab on the investor relations section of the Belite Bio website.

How long will the replay of the presentation be available?

The replay will be archived for 90 days following the presentation date.